Prelude Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Prelude Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-105,000	Closed	-$16K	–	1650
2022 Q3	$16K	Buy	+105,000	New	+$8.85M	﹤0.01%	1285
2022 Q2	–	Sell	-92,900	Closed	-$8.35M	–	2093
2022 Q1	$8.35M	Buy	+92,900	New	+$8.58M	0.24%	60
2020 Q4	–	Sell	-200	Closed	-$22K	–	2073
2020 Q3	$22K	Sell	200 -600	-75%	-$67.3K	﹤0.01%	1317
2020 Q2	$90K	Buy	+800	New	+$78.8K	0.01%	986
2019 Q4	–	Sell	-14,400	Closed	-$1.1M	–	2297
2019 Q3	$1.1M	Buy	+14,400	New	+$1.2M	0.05%	309
2019 Q1	–	Sell	-400	Closed	-$29K	–	2244
2018 Q4	$29K	Buy	+400	New	+$32.2K	﹤0.01%	1201
2016 Q1	–	Sell	-110,000	Closed	-$7.72M	–	1560
2015 Q4	$7.72M	Buy	+110,000	New	+$7.5M	1.2%	6

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Prelude Capital Management's XBI Position: Q3 2025 in Review

Prelude Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2025, closing a stake of 15,000 shares — an estimated $1.24M sold.

Prelude Capital Management first reported a position in XBI in Q1 2015 and held it in 7 quarters. The position peaked at $1.33M in Q2 2021. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

Prelude Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 15,000 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $1.24M.
Prelude Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and held it in 7 quarters.
Prelude Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.33M in Q2 2021.
656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.